Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on May 8)
Down In The Dumps
(Stocks hitting 52-week lows on May 8)
Medical/Healthcare/Biotech Conferences
- 2018 Disruptive Growth and Healthcare Conference – May 8-9, in New York City
- Deutsche Bank 43rd Annual Health Care Conference – May 8-9, at the InterContinental Boston Hotel
See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates
Stocks In Focus
Opko Posts Better-than-expected results
Opko Health Inc. (NASDAQ:OPK) reported a narrower-than-expected Q1 loss of 8 cents per share on above-consensus revenues of $254.9 million.
The stock rallied 6.21 percent to $3.42 in after-hours trading.
Penumbra's Beat-And-Raise Quarter
The stock rallied 5.96 percent to $144 after hours.
Synthetic Biologic Posts Narrower-Than-Expected Loss
Synthetic Biologics Inc (NYSE:SYN) reported a loss of 2 cents per share for its Q1, narrower than the loss of 5 cents expected.
The stock jumped 11.28 percent to $0.2773 in after-hours trading.
OpGen Q1 Beats Estimates
OpGen Inc (NASDAQ:OPGN) reported a narrower-than-expected loss and above-consensus revenues for its Q1.
The stock gained 3.68 percent to $1.97 in after-hours trading.
Transenterix Gains On Q1 Beat
On The Radar
The following companies report earnings on Wednesday:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
